Combination immunotherapy: a road map by F. Stephen Hodi, Jedd D. Wolchok, Howard L. Kaufman, Patrick A. Ott, Jon M. Wigginton

Get full text

A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. by Patrick A Ott, Anne Hamilton, Amanda Jones, Naomi Haas, Tsiporah Shore, Sandra Liddell, Paul J Christos, L Austin Doyle, Michael Millward, Franco M Muggia, Anna C Pavlick

Get full text

A phase II trial of sorafenib in metastatic melanoma with tissue correlates. by Patrick A Ott, Anne Hamilton, Christina Min, Sara Safarzadeh-Amiri, Lauren Goldberg, Joanne Yoon, Herman Yee, Michael Buckley, Paul J Christos, John J Wright, David Polsky, Iman Osman, Leonard Liebes, Anna C Pavlick

Get full text

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

Get full text

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors by Dirk Schadendorf, Ignacio Melero, Robert L Ferris, William Sharfman, Satyendra Suryawanshi, Jaclyn Neely, Fabrice Barlesi, Dung T Le, Jason J Luke, Patrick A Ott, Tina Cascone, Nikhil I Khushalani, Abanti Sanyal, Scott Ely, Manish R Sharma, Deanne Lathers, James L Holloway, Rasika Suryawanshi, Neil H Segal

Get full text